Join
Live feed
·
PRReleasevia Quantisnow
Spyre Therapeutics Inc. logo

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024

ByQuantisnow·Wall Street's wire, on your screen.
SYRE· Spyre Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SYRE (Spyre Therapeutics Inc.) and more on Quantisnow.